Safety in Lactation: Drugs for thromboembolic disorders

What factors should be considered when using LMWH to treat venous thromboembolism in patients with high body weight?

Low molecular weight heparins - should treatment doses be used in patients with renal impairment?

Randomised controlled trials evaluating LMWH efficacy and safety have generally excluded patients with severe renal impairment (RI). In contrast to UFH, LMWHs are primarily cleared…

Low molecular weight heparins - should prophylactic doses be used in patients with renal impairment?

This updated Medicines Q & A reviews the evidence available and considers when prophylactic doses of low molecular weight heparins can be used in patients…

What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

ARCHIVED NPSA Alert - Reducing treatment dose errors with low molecular weight heparins 2010

This page forms part of a resource on medication related patient safety alerts issued  by the National Patient Safety Agency (NPSA) between 2002 and 2012…